Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Donein25on Feb 24, 2023 2:50pm
222 Views
Post# 35304094

RE:RE:RE:Shifting narrative

RE:RE:RE:Shifting narrative Might I add that analysts have no idea what conversations are going on anyway; be it with FDA or with even pharma.

No large pharma is gonna sit on the sidelines and just wait. In this past year, which was a tough one for the sector, CEO after CEO at large pahrmas have talked about looking for deals that make sesne and bring new streams of revenue in the near future... There is fierce competition and no one can just sit back and wait. Plus, do you think a large pharma doesn't want their own people running their own Phase 1 in brain and lung studies?

And who knows if some CEO has already said "lets talk some more after you get BTD" or after AA? Uddin doesn't know and its certainly not factored into his evaluation. A lot can happen in the next one- two years...
<< Previous
Bullboard Posts
Next >>